Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144800 | 0.83 | CHRNA3 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL607998 | 0.78 | NPC1 (0.35) | CHRNB2CHRNA4LTA4HMAPK1 | |
| SCHEMBL10144801 | 0.78 | CHRNA3 (0.37) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL29202395 | 0.75 | MAPK1 (0.52) | MAPK1 | |
| Hydrochloric Acid SCHEMBL29912993 | 0.74 | MAPK1 (0.51) | MAPK1 | |
| SCHEMBL4283292 | 0.72 | SCN9A (0.44) | — | |
| SCHEMBL13705104 | 0.71 | SCN9A (0.43) | MAPK1 | |
| SCHEMBL10145368 | 0.70 | CHRNA3 (0.44) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL16204780 | 0.69 | HCRTR1 (0.46) | MAPK1 | |
| SCHEMBL10144795 | 0.69 | SYK (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CHRNB2 120/4885CHRNA4 69/4885LTA4H 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.